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Background
Heart failure (HF) is frequently associated with renal dys-
function. Thus, therapeutic strategies in HF should not
adversely affect renal function. Cyclic guanosine mono-
phosphate cGMP) is a second messenger generated by
both soluble and particulate guanylate cyclase (sGC and
pGC, respectively). We hypothesized that cGMP activa-
tion of sGC, pGC, or both (by BAY 58-2667, a novel direct
nitric oxide-independent sGC activator [1], and/or the
pGC stimulator B-type natriuretic peptide (BNP)) would
have beneficial renal actions in experimental heart failure.
Methods
Heart failure was induced in 3 groups of dogs (N = 7) by
tachypacing. After 10 days, cardiorenal parameters were
measured at baseline and with two intravenous doses of
BAY 58-2667 (0.1 and 0.3 g/kg/min) or BNP (10 and 50
ng/kg/min) alone or combined. Cardiorenal function was
compared within groups by analysis of variance, while
groups were compared qualitatively.
Results
BAY 58-2667, BNP, and the combination of both
decreased cardiac pre- and afterload and renal perfusion
pressure. BAY 58-2667 alone and in combination with
BNP increased cardiac output and decreased renal vascu-
lar resistance, while BNP alone did not. All three strategies
increased renal blood flow. While BAY 58-2667 alone did
not change urine flow, urinary sodium excretion, or
glomerular filtration rate, these parameters increased with
additional pGC activation. BNP alone increased filtration
fraction, as did the combination with BAY 58-2667. BAY
58-2667 alone and with BNP decreased proximal frac-
tional sodium reabsorption. There was no further activa-
tion of the renin-agiotensin-aldosterone system.
Conclusion
Direct sGC and pGC stimulation results in beneficial car-
diac unloading actions in experimental heart failure, but
only sGC activation increased cardiac output. Despite
reductions in renal perfusion pressure, sGC activation
maintained renal function, while pGC activation
enhanced it. Interestingly, pGC activation increased filtra-
tion fraction and glomerular filtration rate, suggesting
that it increases effective filtration pressure and/or the
coefficient of filtration, whereas sGC activation does not.
These findings suggest that both sGC and pGC activation
do not adversely affect renal function in experimental
heart failure and that co-activation may be a beneficial
strategy in the treatment of heart failure to enhance cardi-
orenal function.
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